Literature DB >> 20373052

Simultaneous over activation of EGFR, telomerase (h TERT), and cyclin D1 correlates with advanced disease in larynx squamous cell carcinoma: a tissue microarray analysis.

Aristeidis Chrysovergis1, Vasilios G Gorgoulis, Ioannis Giotakis, Evangelos Tsiambas, Andreas Karameris, Christos Kittas, Aspasia Kyroudi.   

Abstract

Overexpression of Epidermal Growth Factor Receptor (EGFR) and also of cell cycle control proteins, such as cyclin D1 is a frequent event in squamous cell carcinoma of the larynx (LSSC). Our aim was to correlate their protein levels with telomerase catalytic subunit (h-TERT) expression. Using tissue microarray technology, fifty-five paraffin embedded histologically confirmed primary LSSCs and also ten dysplastic lesions were cored at a diameter of 1.5 mm. Immunohistochemistry (IHC) was performed by the use of anti-EGFR, anti-cyclin D1, and anti-h TERT monoclonal antibodies. Chromogenic in situ hybridization (CISH) analysis was also applied using EGFR gene and chromosome 7 probes, respectively. EGFR, cyclin D1 and h-TERT protein overexpression was observed in 48/55 (87.2%), 19/55 (34.5%) and 21/55 (38.1%) carcinoma cases, respectively. EGFR protein expression was statistically associated with grade (P=0.01), and also with stage (P=0.001) of the examined tumors. Borderline statistical significance was assessed correlating overall cyclin D1 expression to h TERT expression (P=0.06). Simultaneous up regulation of the three proteins was established in 7/55 (12.7%) cases, correlated to the stage of the tumors (P=0.05). EGFR gene amplification was observed in 7/65 (10.7%) carcinomas and dysplasias, whereas chromosome 7 aneuploidy was detected in 4/65 (6.1%) of those cases.Simultaneous up regulation of EGFR, cyclin D1 and h TERT proteins correlates with advanced stage in LSCC. EGFR gene amplification and not only protein over expression maybe is the eligible criterion for targeted therapeutic strategies in those patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373052     DOI: 10.1007/s12032-010-9522-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  29 in total

1.  The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter.

Authors:  Y S Cong; J Wen; S Bacchetti
Journal:  Hum Mol Genet       Date:  1999-01       Impact factor: 6.150

2.  Quantitative measurement of telomerase catalytic subunit (hTERT) mRNA in laryngeal squamous cell carcinomas.

Authors:  B Luzar; M Poljak; I J Marin; J Fischinger; N Gale
Journal:  Anticancer Res       Date:  2001 Nov-Dec       Impact factor: 2.480

3.  Telomerase activity is upregulated in laryngeal squamous cell carcinoma.

Authors:  A J Curran; P J Gullane; J Irish; C Macmillan; J Freeman; S Kamel-Reid
Journal:  Laryngoscope       Date:  2000-03       Impact factor: 3.325

Review 4.  New approaches to the understanding of the molecular basis of oral cancer.

Authors:  V Patel; C Leethanakul; J S Gutkind
Journal:  Crit Rev Oral Biol Med       Date:  2001

5.  p53, Ki67 and cyclin D1 as prognosticators of lymph node metastases in laryngeal carcinoma.

Authors:  D Mielcarek-Kuchta; J Olofsson; W Golusinski
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-10-09       Impact factor: 2.503

6.  Different risk factors in basaloid and common squamous head and neck cancer.

Authors:  Britta Kleist; Alexander Bankau; Gerd Lorenz; Bernd Jäger; Micaela Poetsch
Journal:  Laryngoscope       Date:  2004-06       Impact factor: 3.325

7.  Telomerase catalytic subunit in laryngeal carcinogenesis--an immunohistochemical study.

Authors:  Bostjan Luzar; Mario Poljak; Nina Gale
Journal:  Mod Pathol       Date:  2005-03       Impact factor: 7.842

8.  Distribution and prognostic significance of cell cycle proteins in squamous carcinoma of the larynx, hypopharynx and adjacent epithelial hyperplastic lesions.

Authors:  Metka Volavsek; Matej Bracko; Nina Gale
Journal:  J Laryngol Otol       Date:  2003-04       Impact factor: 1.469

Review 9.  Molecular targeted therapy of head and neck cancer: review and clinical development challenges.

Authors:  Christophe Le Tourneau; Sandrine Faivre; Lillian L Siu
Journal:  Eur J Cancer       Date:  2007-09-27       Impact factor: 9.162

Review 10.  Predictive factors of neck metastases in laryngeal squamous cell carcinoma. Towards an integrated clinico-molecular classification.

Authors:  G Almadori; F Bussu; G Paludettii
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-12       Impact factor: 2.124

View more
  5 in total

1.  Identification of candidate molecular markers of nasopharyngeal carcinoma by tissue microarray and in situ hybridization.

Authors:  Shilong Xiong; Qian Wang; Lei Zheng; Feng Gao; Junling Li
Journal:  Med Oncol       Date:  2010-11-05       Impact factor: 3.064

2.  Increased telomerase activity and hTERT expression in human salivary gland carcinomas.

Authors:  Hideo Shigeishi; Masaru Sugiyama; Hidetoshi Tahara; Shigehiro Ono; Ujjal Kumar Bhawal; Masaya Okura; Mikihiko Kogo; Masanori Shinohara; Masanobu Shindoh; Satoru Shintani; Hiroyuki Hamakawa; Takashi Takata; Nobuyuki Kamata
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

3.  Cyclin D1 expression in Bowen's disease and cutaneous squamous cell carcinoma.

Authors:  Yanyun Shen; Jinhua Xu; Jin Jin; Hui Tang; Jun Liang
Journal:  Mol Clin Oncol       Date:  2014-04-01

4.  Effects of systemic administration of HESA-A on the expression of cyclin D1 and EGFR and E-cadherin in the induced tongue dysplasia in rats.

Authors:  Shirin Fattahi; Sepideh Vosough Hosseini; Amir Ala Aghbali; Masoumeh Mehdipour; Sanaz Helli; Hossein Damghani
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2017-12-13

Review 5.  Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications.

Authors:  Paolo Boscolo-Rizzo; Maria Cristina Da Mosto; Enrica Rampazzo; Silvia Giunco; Annarosa Del Mistro; Anna Menegaldo; Lorena Baboci; Monica Mantovani; Giancarlo Tirelli; Anita De Rossi
Journal:  Cancer Metastasis Rev       Date:  2016-09       Impact factor: 9.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.